A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. (2017)
Attributed to:
Manchester Academic Health Science Centre Technology Hub: Clinical Proteomics Centre for Stratified Medicine
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.199
PubMed Identifier: 28664912
Publication URI: http://europepmc.org/abstract/MED/28664912
Type: Journal Article/Review
Volume: 117
Parent Publication: British journal of cancer
Issue: 5
ISSN: 0007-0920